Invitae Corporation (NVTA) Research

Invitae Corporation operates as a medical genetics enterprise, striving to integrate genetic insights into mainstream medical practice to enhance healthcare outcomes for individuals in the United States, Canada, and internationally. The company provides a comprehensive suite of offerings, including genetic testing for various clinical specializations such as hereditary cancer, cardiovascular health, neurological disorders, pediatric conditions, oncology, metabolic ailments, and rare diseases, alongside digital health tools and health data services. Its clientele spans individual patients, healthcare providers, biopharmaceutical firms, and other collaborators. Established in 2010 as Locus Development, Inc., the company officially became Invitae Corporation in 2012 and is headquartered in San Francisco, California.

Market snapshot

Symbol
NVTA
Price
$0.02
Day change
-35.59%
Market cap
$5.4M
P/E ratio
-0.00x
52-week range
0.015-2.34
Sector
Healthcare
Industry
Medical - Diagnostics & Research
Analyst price target
$9.75

Peer companies

  • Fresh Tracks Therapeutics, Inc. (FRTX)
  • Greenbrook TMS Inc. (GBNH)
  • LumiraDx Limited (LMDX)
  • NanoString Technologies, Inc. (NSTG)
  • Holdco Nuvo Group D.G Ltd. Ordinary Shares (NUVO)
  • Obalon Therapeutics, Inc. (OBLN)
  • Regional Health Properties, Inc. (RHE)
  • Regional Health Properties, Inc. (RHEP)

Recent insider activity

  • Nussbaum Robert L — F-InKind (17404 shares) on 2023-12-20
  • Brida Thomas — F-InKind (17404 shares) on 2023-12-20
  • Sholehvar David — A-Award (850000 shares) on 2023-11-13
  • Sholehvar David — trade (0 shares) on 2023-11-13
  • Brida Thomas — A-Award (229500 shares) on 2023-10-18

Open Invitae Corporation (NVTA) in Thesis for live fundamentals, charts, options context, and portfolio-aware Copilot follow-ups.